Maplight Therapeutics (NASDAQ:MPLT) Shares Down 6.4% – What’s Next?

Posted by Stanley Muller on Aug 9th, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report)’s stock price dropped 6.4% during trading on Friday . The company traded as low as $12.30 and last traded at $12.43. 102,568 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 453,138 shares. The stock had previously closed at $13.28.

Analysts Set New Price Targets

Several brokerages have recently commented on MPLT. UBS Group raised their target price on Maplight Therapeutics from $48.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Needham & Company LLC boosted their price objective on Maplight Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Friday, July 10th. Wall Street Zen cut Maplight Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. BMO Capital Markets assumed coverage on shares of Maplight Therapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $46.00 price target for the company. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $34.42.

Check Out Our Latest Stock Report on Maplight Therapeutics

Maplight Therapeutics Stock Down 8.4%

The company has a market cap of $518.69 million and a P/E ratio of -0.30. The company’s 50-day moving average is $29.00 and its two-hundred day moving average is $24.69.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, analysts anticipate that Maplight Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Christopher A. Kroeger sold 118,235 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the completion of the transaction, the chief executive officer owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. This represents a 7.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox acquired 15,620 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average cost of $9.52 per share, with a total value of $148,702.40. Following the acquisition, the director owned 15,620 shares in the company, valued at $148,702.40. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders sold 154,297 shares of company stock valued at $3,912,656 over the last ninety days. 3.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maplight Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Fcpm Iii Services B.V. bought a new stake in shares of Maplight Therapeutics in the fourth quarter valued at approximately $56,672,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at approximately $49,168,000. Goldman Sachs Group Inc. bought a new position in Maplight Therapeutics in the 4th quarter worth approximately $34,026,000. BlackRock Inc. bought a new position in Maplight Therapeutics in the 2nd quarter worth approximately $36,741,000. Finally, Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the 4th quarter valued at approximately $17,060,000.

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.